Maryam Tehranipour | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Maryam Tehranipour | Pharmacology | Best Researcher Award

Animal Physiology | Islamic Azad University | Iran

Dr. Maryam Tehranipour is an accomplished Associate Professor in the Department of Biology at the Islamic Azad University, Mashhad, Iran, recognized for her distinguished contributions to the fields of diabetes, metabolic disorders, neurobiology, oxidative stress, and cancer biology. Holding a Ph.D. in Animal Physiology, she has built a dynamic academic and research career integrating cellular physiology, pharmacology, and molecular mechanisms of disease. Her extensive publication record spans a broad spectrum of biomedical investigations, including neuroprotective strategies, natural product pharmacology, nanomedicine, and experimental models of diabetes and neurodegeneration. Dr. Tehranipour’s pioneering studies have elucidated the roles of oxidative damage, angiogenesis, and neuronal regeneration in disease progression and therapeutic recovery, particularly highlighting the potential of bioactive compounds and nanocarrier systems in drug design and targeted therapy. Her collaborative work has advanced understanding of diabetic complications, nerve injury repair, and cancer cell modulation through natural and synthetic agents. Beyond her prolific research output, she has played a significant role in mentoring undergraduate, graduate, and doctoral students, fostering scientific rigor and innovation in physiological research. Her scholarly influence is reflected through her indexed publications, contributions to interdisciplinary research networks, and global collaborations that link physiology, biochemistry, and nanotechnology for translational health impact. Dr. Tehranipour’s scientific endeavors emphasize the integration of experimental biology with clinical relevance, aiming to bridge laboratory discoveries with therapeutic applications. Through her ongoing research, she continues to contribute meaningfully to global biomedical science, particularly in developing sustainable and biologically safe therapeutic interventions addressing chronic and degenerative diseases that pose major public health challenges. She has 238 citations from 53 documents with an h-index of 9.

Profile: Scopus 

Featured Publications

1. The Umbelliprenin-CTAB cellulose nanocrystal delivery system prevents hyperglycemia in diabetic rats by activating the insulin receptor IR/PDK1 pathway. (2025). Scientific Reports. Open access.

2. The effects of N-butanol and ethyl acetate fractions of Ferula asafoetida hydroalcoholic extract on the expression of VEGF and FGF genes in the chorioallantoic membrane of chick embryos. (2025). Journal of Veterinary Research.Open access.

3. Bimetallic-based colorimetric aptasensor for the quantitative analysis of ampicillin using catalytic activity of ZrFe metal–organic framework and terminal deoxynucleotidyl transferase-assisted signal amplification. (2025). Bionanoscience. Open access.

4. The effect of Ziziphora clinopodioides hydroalcoholic extract on the neuronal density and histopathology of the hippocampal area CA2 in streptozotocin-induced Alzheimer’s model in male rats. (2025). Journal of Chemical Health Risks. Open access.

5. A novel alpha-terpineol-loaded niosome formulation coated with hyaluronic acid and evaluation of its anticancer properties in vitro. (2025). Journal of Molecular Liquids. Open access.

Reham Abdelkader | Pharmacology | Best Researcher Award

Published on by Health Scientists

Prof. Reham Abdelkader | Pharmacology | Best Researcher Award 

Head of department | German university in Cairo | Egypt

Dr. Reham Mahmoud Abdel-Kader, Professor of Pharmacology and Toxicology and Chair of the Department at the German University in Cairo, is a distinguished biomedical scientist whose research bridges molecular pharmacology, neurodegenerative diseases, and cancer biology with translational therapeutic innovation. Her scientific contributions focus on elucidating mitochondrial dysfunction, neuroinflammation, and cellular bioenergetics as critical mechanisms in Alzheimer’s disease and oncological disorders, advancing targeted treatment approaches through nanotechnology and pharmacogenomic insights. Dr. Abdel-Kader has established two active research groups investigating Alzheimer’s pathology and mitochondrial roles in breast cancer progression, fostering a strong translational link between bench discovery and therapeutic development. She has published widely in internationally recognized journals in pharmacology, neurobiology, and molecular medicine, and her work has received global recognition through prestigious conference presentations and features in leading scientific outlets. Her research has attracted significant international funding from agencies such as the Swiss National Science Foundation, DAAD-BMBF, and the Science and Technology Development Fund, reflecting the impact and sustainability of her scientific endeavors. A committed academic leader, she has played a vital role in curriculum development, accreditation processes, and capacity-building initiatives that enhance educational quality and research excellence within her institution. Dr. Abdel-Kader actively collaborates with leading scientists and institutions across Europe, including partnerships in Germany and Switzerland, fostering international scientific exchange and innovation. Her patent in nanocomposite synthesis further underscores her commitment to bridging pharmaceutical research and technology-based solutions. Through her scholarly rigor, mentorship, and collaborative leadership, Dr. Abdel-Kader continues to contribute significantly to global pharmacological sciences and to shaping the next generation of health researchers dedicated to advancing human health and societal well-being.

Profiles: Google Scholar | ORCID

Featured Publications

1. Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., & others. (2007). Mitochondrial dysfunction: The first domino in brain aging and Alzheimer’s disease? Antioxidants & Redox Signaling,

2. Abdel-Kader, R., Hauptmann, S., Keil, U., Scherping, I., Leuner, K., Eckert, A., & others. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research,

3. Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., & others. (2012). Mitochondrial dysfunction—A pharmacological target in Alzheimer’s disease. Molecular Neurobiology,

4. Franke, C., Nöldner, M., Abdel-Kader, R., Johnson-Anuna, L. N., Wood, W. G., & others. (2007). Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiology of Disease

5. Eckert, G. P., Schiborr, C., Hagl, S., Abdel-Kader, R., Müller, W. E., & Rimbach, G. (2013). Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochemistry International.

Sipping Kemegne Marius Tresor | Pharmacology | Best Researcher Award

Published on by Health Scientists

Dr. Sipping Kemegne Marius Tresor | Pharmacology | Best Researcher Award

Research scholar | Slovak Academy of Sciences | Slovakia

Dr. Sipping Kemegne Marius Tresor is a biochemist and postdoctoral research fellow whose expertise spans immunopharmacology, cancer biology, inflammatory diseases, and phytomedicine, with a focus on natural bioactive compounds and their translational therapeutic applications. Trained at leading institutions across Africa and Europe, he has developed a strong multidisciplinary foundation integrating molecular biology, pharmacology, biotechnology, and clinical research principles to advance innovation in precision therapeutics. His research has pioneered the exploration and characterization of polysaccharide-rich bioactive fractions from medicinal fungi, particularly Ganoderma species, elucidating their antioxidant, anti-inflammatory, and anti-metastatic potentials and offering promising chemopreventive and therapeutic leads for cancer and immune-mediated disorders. His scientific contributions include peer-reviewed publications in internationally indexed journals and authorship of a scholarly book, demonstrating sustained commitment to advancing biomedical knowledge and global research excellence. Dr. Sipping’s work has been strengthened through impactful collaborations across Africa, Europe, and Asia with prominent scientists and international research groups, fostering interdisciplinary partnerships and capacity building in natural product research and immunotherapeutics. His ongoing investigations focus on isolating novel polysaccharides and developing nanotechnology-enabled drug delivery systems to enhance therapeutic efficacy against chronic inflammatory conditions, such as rheumatoid arthritis, bridging traditional bioresources with cutting-edge biomedical strategies. Beyond laboratory research, he is a certified clinical research professional committed to strengthening translational pathways from preclinical discovery to potential clinical application. His membership in distinguished scientific bodies reflects his dedication to contributing to the global research community. Driven by the vision to harness bioresources and advanced biotechnology for improved public health, Dr. Sipping aims to deliver innovative, accessible, and safe therapeutic options addressing cancer, autoimmune, and infectious diseases, thereby contributing to scientific progress and societal well-being. He has 81 citations from 9 documents with an h-index of 5.

Profiles:  Scopus | ORCID

Featured Publications

1. Sipping, M., Thakur, D., Singh, B., Njamen, D., & Mukherjee, S. (2025). Polysaccharide extract of Ganoderma resinaceum restricts breast cancer progression in vitro by intervening in epithelial–mesenchymal transition and cancer stemness. Revista Brasileira de Farmacognosia.

2. Sipping, M., Sathish Kumar, T., & Kamdem, N. (2025). Scientific investigation on antibacterial, antioxidant, cytotoxic effects and TLC bioautography of Terminalia schimperiania stem bark extracts. Journal of Complementary and Integrative Medicine.

3. Kamga Silihe, K., Defo Mbou, W., Ngo Pambe, J. C., Kenmogne, L. V., Fotso Maptouom, L., Kemegne Sipping, M. T., Zingue, S., & Njamen, D. (2023). Comparative anticancer effects of Annona muricata Linn (Annonaceae) leaves and fruits on DMBA-induced breast cancer in female rats. BMC Complementary Medicine and Therapies.

4. Nana Tchoupang, E., Yadji, V., Wangbara, J. B., Kemegne Sipping, M. T., Zingue, S., Njamen, D., & Mutalik, S. (2022). In vitro and in vivo antiproliferative actions of Solanum gilo Raddi (Solanaceae) fruit extract on breast tissues. Advances in Pharmacological and Pharmaceutical Sciences.

5. Kamga Silihe, K., Zingue, S., Kemegne Sipping, M. T., Busuioc Cazanevscaia, A., Dediu Botezatu, A. V., Njamen, D., & Dinica, R. M. (2022). The antioxidant potential of Ficus umbellata Vahl (Moraceae) that accelerates in vitro and in vivo anti-inflammatory protective effects. Applied Sciences.

Maxim Evstigneev | Pharmacology | Best Researcher Award

Published on by Health Scientists

Prof. Dr. Maxim Evstigneev | Pharmacology | Best Researcher Award 

Director | Sevastopol State University | Russia

Dr. Maxim Pavlovich Evstigneev is the Director of the Institute for Advanced Studies at Sevastopol State University, Russian Federation. He earned his Ph.D. and Doctor of Science (DrSci) in Biophysics and was later appointed Full Professor of Physics. Dr. Evstigneev’s research focuses on the thermodynamics of drug interactions, biophysical chemistry, and nanoparticle interactions, with pioneering contributions in understanding DNA-binding drug mechanisms and the biomedical potential of C60 fullerenes. He has authored numerous peer-reviewed journal articles and several scientific books, including DNA-binding Aromatic Drug Molecules: Physico-chemical Interactions and Their Biological Roles and Structure, Thermodynamics and Energetics of Drug-DNA Interactions. His scientific impact is reflected through extensive citations and global recognition. Dr. Evstigneev has received multiple prestigious honors, including awards from the Cabinet of Ministers of Ukraine, the President of Ukraine Award to Young Scientists, and recognition as the youngest Doctor of Sciences in Ukraine. He has also led several national and international research grants supported by major scientific foundations and institutions. Beyond research, he serves as Guest Editor for Organic Chemistry International Journal and was an Editorial Board Member of BioMed Research International. Currently, he is Vice-President of the Crimean Academy of Sciences and a recognized expert for the Russian Academy of Sciences, exemplifying leadership and excellence in molecular biophysics and nanomaterials research. He has 2564 citations from 191 documents with an h-index of 28.

Profiles: Google Scholar | Scopus

Featured Publications

1. The Fundamental Origin of the Polar Contribution to Heat Capacity Changes in Hydration in an Aqueous Solution. (2025). Journal of Physical Organic Chemistry.

2. The Correlated States Theory of the Hydrophobic Effect. (2025). Journal of Physical Chemistry B.

3. Valsartan – Choline: Preparation, Characterization, and Transdermal Permeation. (2025). Journal of Molecular Liquids.

4. Rationalizing DLS Size Distributions of Fullerene Conjugates. (2024). Letter Article.

5.New PMMA-Based Hydroxyapatite/ZnFe₂O₄/ZnO Composite with Antibacterial Performance and Low Toxicity. (2023). Biomimetics.

Siyu Chen | Pharmacology | Best Researcher Award

Published on by Health Scientists

 Prof. Siyu Chen | Pharmacology | Best Researcher Award

Professor | China Pharmaceutical University | China

Dr. Chen Siyu currently serves as the Deputy Director of the Department of Biochemistry at the School of Life Sciences and Technology, China Pharmaceutical University, where he is also a Professor, Doctoral Supervisor, and Chief Young Scientist of the National Key Research and Development Program. He obtained his academic training in biochemistry and molecular biology, cultivating a strong foundation in metabolic and biochemical sciences. Dr. Chen’s research primarily focuses on Target Discovery and Intervention Strategies for Metabolic Diseases, aiming to elucidate molecular mechanisms and identify novel therapeutic targets for metabolic regulation. He has published extensively as first or corresponding author in leading international journals such as Advanced Science, Nature Communications, and Gut Microbes, with his work widely cited by peers. His innovative research has led to the granting of national patents and multiple ongoing patent applications. Dr. Chen has successfully led major research projects under national and provincial funding programs, including the National Key R&D Program for Young Scientists, the National Natural Science Foundation for Young Scientists, and the Jiangsu Province Excellent Youth Fund. Recognized for his scholarly excellence, he received the Outstanding Doctoral Dissertation Award of Jiangsu Province. In addition to his research, Dr. Chen contributes actively to the academic community as a Young Member of the Metabolism Committee of the Chinese Society of Biochemistry, Director of the Jiangsu Society of Developmental Biology, and Editorial Board Member of Journal of China Pharmaceutical University and Progress in Biochemistry and Biophysics. He also serves as a Guest Editor for Frontiers in Endocrinology and a regular reviewer for leading journals including Journal of Hepatology and ACS Nano. He has 1616 citations from 60 documents with an h-index of 24.

Profiles: Scopus | ORCID

Featured Publications

1. Photosensitive biomimetic nanomedicine-mediated recombination of adipose microenvironments for antiobesity therapy. (2025). Advanced Materials.

2. Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity. (2025). Bioengineering and Translational Medicine.

3. Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex. (2024). Cell Communication and Signaling.

4. Luteolin detoxifies DEHP and prevents liver injury by degrading Uroc1 protein in mice. (2024). EMBO Molecular Medicine.

5. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. (2024). Phytomedicine.